Open-Label, Phase I, Pharmacokinetic Studies in Healthy Chinese Subjects to Evaluate the Bioequivalence and Food Effect of a Novel Formulation of Abiraterone Acetate Tablets-Reference-Cited by-同舟云学术

Open-Label, Phase I, Pharmacokinetic Studies in Healthy Chinese Subjects to Evaluate the Bioequivalence and Food Effect of a Novel Formulation of Abiraterone Acetate Tablets

Published:2022-01 Issue: Volume:Volume 16 Page:3-12
ISSN:1177-8881
Container-title:Drug Design, Development and Therapy
language:en
Short-container-title:DDDT

Author:

Feng Zeying,Liu Yaxin,Kuang Yun,Yang Shuang,Li Jinlei,Ye Ling,Huang Jie,Pei Qi^ORCID,Huang Yuanyuan,Yang Guoping^ORCID

Publisher

Informa UK Limited

Subject

Drug Discovery,Pharmaceutical Science,Pharmacology

Reference22 articles.

1. Cancer.Net. Prostate cancer: statistics; 2021. Available from: https://www.cancer.net/cancer-types/prostate-cancer/statistics. Accessed September 15, 2021.

2. Global incidence of prostate cancer in developing and developed countries with changing age structures

3. Phase I Clinical Trial of the CYP17 Inhibitor Abiraterone Acetate Demonstrating Clinical Activity in Patients With Castration-Resistant Prostate Cancer Who Received Prior Ketoconazole Therapy

4. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study

5. Abiraterone acetate and its use in the treatment of metastatic prostate cancer: a review

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Abiraterone, a rare cause of severe perioperative hypokalemia with unusual presentation as aphonia and quadriparesis: a case report;Ain-Shams Journal of Anesthesiology;2023-11-20

2. Effect of food and polymorphisms in SLCO2B1, CYP3A4 and UGT1A4 on pharmacokinetics of abiraterone and its metabolites in Chinese volunteers;British Journal of Clinical Pharmacology;2023-09-18

3. Increasing the efficacy of abiraterone - from pharmacokinetics, through therapeutic drug monitoring to overcoming food effects with innovative pharmaceutical products;European Journal of Pharmaceutical Sciences;2022-09